(Total Views: 636)
Posted On: 06/02/2020 6:46:29 AM
Post# of 154993
RUXOLITINIB article from the UK claiming it 'works'
https://www.dailymail.co.uk/health/article-83...acebo.html
Ninety percent of severely ill adults with coronavirus who were treated with a drug for children's immune disease started recovering within two weeks compared to those who got a placebo
Ruxolitinib is a drug used to treat Hemophagocytic Lymphohistiocytosis (HLH), a severe systemic inflammatory syndrome in children that can be fatal
Scientists believe it can prevent cytokine storms, which occur when the body doesn't just fight off the virus but also attacks its own cells and tissues
90% of coronavirus patients who received the drug saw respiratory improvements in two weeks compared to those who received a placebo
Three patients in the control group died but no severely ill patients who were given ruxolitinib passed away
Ruxolitinib is approved to treat Hemophagocytic Lymphohistiocytosis (HLH), which is a severe systemic inflammatory syndrome among youngsters that can be fatal, by calming down the immune system's overreaction.
Scientists from Cincinnati Children's Hospital in Ohio say that 10 times as many patients who received the medication saw improvements in their respiratory health compared to those who were given a placebo.
In addition, patients who didn't receive ruxolitinib were 14 percent more likely to die than those who did.
https://www.dailymail.co.uk/health/article-83...acebo.html
Ninety percent of severely ill adults with coronavirus who were treated with a drug for children's immune disease started recovering within two weeks compared to those who got a placebo
Ruxolitinib is a drug used to treat Hemophagocytic Lymphohistiocytosis (HLH), a severe systemic inflammatory syndrome in children that can be fatal
Scientists believe it can prevent cytokine storms, which occur when the body doesn't just fight off the virus but also attacks its own cells and tissues
90% of coronavirus patients who received the drug saw respiratory improvements in two weeks compared to those who received a placebo
Three patients in the control group died but no severely ill patients who were given ruxolitinib passed away
Ruxolitinib is approved to treat Hemophagocytic Lymphohistiocytosis (HLH), which is a severe systemic inflammatory syndrome among youngsters that can be fatal, by calming down the immune system's overreaction.
Scientists from Cincinnati Children's Hospital in Ohio say that 10 times as many patients who received the medication saw improvements in their respiratory health compared to those who were given a placebo.
In addition, patients who didn't receive ruxolitinib were 14 percent more likely to die than those who did.
(0)
(0)
